Mandate

Vinge advises Ambea on its acquisition of Aleris Care

October 16, 2018 Banking and Finance

Vinge has advised Ambea on its acquisition of Aleris’ care operations (“Aleris Care”) from Sirela Sweden AB, which is indirectly owned by Investor through Patricia Industries.

The purchase price amounted to SEK 2.6 billion on a debt free case free basis. Aleris Care is the leader in the private market for care services in Norway, the sixth largest private operator in Sweden and the largest private provider in the Denmark. Today, Ambea is the second largest player in the private market for care services in Sweden and the seventh largest in Norway. Following the acquisition, Ambea will be the largest care provider in the Nordic region with operations in Sweden, Norway and Denmark. The transaction is subject to regulatory approval by the relevant competition authorities and closing is expected to occur during the first quarter of 2019.
 
Vinge’s team consisted of partners Christina Kokko (M&A), Charlotte Levin (Public M&A and Capital Markets), Albert Wållgren (Banking and Finance) and Johan Karlsson (Competition) together with associates Johanna Wiberg, Martin Cronsioe and Karolina Cohrs (M&A), Linn Adelwald, Josefine Lanker and Josefine Larsson (Banking and Finance), Nicklas Thorgerzon, Fredrika Hjelmberg, Hayaat Ibrahim and Victor Berg (Commercial Agreements), Klara Secher (IP), Kristoffer Larson (Real Estate), Sara Strandberg and Lisa Ullman (Employment), Trine Osen Bergqvist, Xandra Ståhlberg and Sofia Landolsi (Competition), Hannes Pettersson (Corporate), Maria Schultzberg, Victor Ericsson and Henrik Wastenson (Tax) and VDR assistant Jessica Öijer. 

Selmer (Norway) and Accura (Denmark) has advised on the transaction’s Norwegian and Danish legal and tax aspects. 
 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025